Life-saving overdose drug available at deep discount
Upcoming Events
Related News
A nasal spray crucial in saving the lives of people in the middle of an opiate drug overdose will be available at 40 percent off.
Deaths from heroin overdoses have increased six-fold between 2001 and 2014, outpacing overdose deaths from cocaine, tranquilizers and prescription opioid pain killers in the same time period.
Local emergency rooms, rescue services and police are scrambling to keep up with the rash of overdoses. One of their prime weapons is the drug naloxone.
On Jan. 14 as the White House Office of National Drug Control Policy hosted a community forum on the opioid epidemic in Knox County, Tenn., state and local leaders announced an expansion of efforts to facilitate public agencies’ access to potentially lifesaving opioid withdrawal medication.
NACo Podcasts: Counties & National Drug Control Policy
NACo, the National Governors Association, National League of Cities and U.S. Conference of Mayors, with the U.S. Communities Government Purchasing Alliance and Premier, Inc., have reached an agreement with Adapt Pharma to offer Narcan Nasal Spray at a 40- percent discount, or $37.50 per dose ($75 for a 2-pack carton).
Narcan Nasal Spray, is the only FDA-approved, ready-to-use nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose.
“Medication-assisted opioid treatment can mean the difference between life and death,” said NACo President Sallie Clark, commissioner, El Paso County, Colo. “We see the devastating effects of prescription drug abuse and heroin use because counties are at the intersection of the local health, justice and public safety systems. We welcome this public-private partnership to support our response to this national crisis.”
As part of its Safe and Secure Counties Initiative, NACo is working with state associations of counties to develop policy recommendations and promote promising practices to address the opioid epidemic plaguing communities.
The White House National Drug Policy Control Director Michael Botticelli praised the agreement between Adapt Pharma and the U.S. Communities Government Purchasing Alliance.
“The Administration has made it a top priority to expand access to the overdose reversal drug naloxone and medication-assisted treatment because we have lost too many of our family members and friends to the opioid epidemic. This public-private partnership to secure discounts for state and local agencies can help ensure that these life-saving medications are available wherever they are needed.”
For more information about Narcan Nasal Spray, click here.
Attachments
Related News
SAMHSA releases new 2024 data on rates of mental illness and substance use disorder in the U.S.
On July 28, the U.S. Department of Health and Human Services’ (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) released the findings of its annual National Survey on Drug Use and Health (NSDUH), which provides data on rates of substance use and mental illness at the national, state and local level.
Congress introduces bipartisan legislation to strengthen rural health care access and funding
Rural communities face unique health care challenges, from provider shortages to funding disparities. To address these concerns, the U.S. Senate recently introduced two bipartisan bills aimed at improving rural health care access and funding: the Rural Health Focus Act and the Fair Funding for Rural Hospitals Act.
HALT Fentanyl Act signed into law
On July 16, the Halt All Lethal Trafficking of Fentanyl Act (HALT Fentanyl Act) (P.L. 119-26) was signed into law, marking a major turning point in the nation’s response to the opioid epidemic. The bipartisan legislation permanently classifies fentanyl-related substances (FRS) as Schedule I drugs under the Controlled Substances Act, granting law enforcement the authority to combat the growing threat posed by synthetic opioids. The law’s enactment follows years of temporary extensions that placed these substances under federal control on a provisional basis.